Rapid Relapse after Resection of a Sunitinib-resistant Gastrointestinal Stromal Tumor Harboring a Secondary Mutation in Exon 13 of the c-KIT Gene

被引:0
作者
Kikuchi, Hrotoshi [1 ]
Miyazaki, Shinichiro [1 ]
Setoguchi, Tomohiko [1 ]
Hiramatsu, Yoshihiro [1 ]
Ohta, Manabu [1 ]
Kamiya, Kinji [1 ]
Sakaguchi, Takanori [1 ]
Konno, Hiroyuki [1 ]
机构
[1] Hamamatsu Univ Sch Med, Dept Surg 2, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan
关键词
Gastrointestinal stromal tumor; sunitinib; resistance; surgical intervention; c-KIT mutation; TYROSINE-KINASE INHIBITOR; OF-FUNCTION MUTATIONS; IMATINIB MESYLATE; ACQUIRED-RESISTANCE; THERAPY; ACTIVATION; EFFICACY; DISEASE; SURGERY; PATIENT;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We describe a case with rapid relapse after resection of a sunitinib-resistant gastrointestinal stromal tumor (GIST). Liver metastases and foci of left retroperitoneal recurrence developed during adjuvant imatinib treatment. The tumors did not shrink after sunitinib treatment, and hepatectomy and retroperitoneal tumorectomy were performed. Histological examination showed a Ki67 labeling index of over 50% in viable tumor cells. Genomic analysis revealed mutations in exons 11 and 13 of the c-KIT gene. Computed-tomographic scan revealed retroperitoneal recurrence at the surgical site five weeks post-operatively. In this case, high proliferative activity of the recurrent foci was associated with resistance to sunitinib and rapid recurrence during the perioperative withdrawal of sunitinib. It is important to consider the possibility of an exon 13 mutation with an aggressive phenotype when treating sunitinib-resistant GISTs. Surgical intervention for sunitinib-resistant GISTs should be carefully considered if R0 resection is not possible.
引用
收藏
页码:4105 / 4109
页数:5
相关论文
共 27 条
[1]   Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation [J].
Antonescu, CR ;
Besmer, P ;
Guo, TH ;
Arkun, K ;
Hom, G ;
Koryotowski, B ;
Leversha, MA ;
Jeffrey, PD ;
Desantis, D ;
Singer, S ;
Brennan, MF ;
Maki, RG ;
DeMatteo, RP .
CLINICAL CANCER RESEARCH, 2005, 11 (11) :4182-4190
[2]  
Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139
[3]   A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors [J].
Chen, LL ;
Trent, JC ;
Wu, EF ;
Fuller, GN ;
Ramdas, L ;
Zhang, W ;
Raymond, AK ;
Prieto, VG ;
Oyedeji, CO ;
Hunt, KK ;
Pollock, RE ;
Feig, BW ;
Hayes, KJ ;
Choi, H ;
Macapinlac, HA ;
Hittelman, W ;
Velasco, MA ;
Patel, S ;
Burgess, MA ;
Benjamin, RS ;
Frazier, ML .
CANCER RESEARCH, 2004, 64 (17) :5913-5919
[4]   Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria [J].
Choi, Haesun ;
Charnsangavej, Chuslip ;
Faria, Silvana C. ;
Macapinlac, Homer A. ;
Burgess, Michael A. ;
Patel, Shreyaskumar R. ;
Chen, Lei L. ;
Podoloff, Donald A. ;
Benjamin, Robert S. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) :1753-1759
[5]   Results of tyrosine-kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor [J].
DeMatteo, Ronald P. ;
Maki, Robert G. ;
Singer, Samuel ;
Gonen, Mithat ;
Brennan, Murray F. ;
Antonescu, Cristina R. .
ANNALS OF SURGERY, 2007, 245 (03) :347-352
[6]   Two hundred gastrointestinal stromal tumors - Recurrence patterns and prognostic factors for survival [J].
DeMatteo, RP ;
Lewis, JJ ;
Leung, D ;
Mudan, SS ;
Woodruff, JM ;
Brennan, MF .
ANNALS OF SURGERY, 2000, 231 (01) :51-58
[7]   Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial [J].
Demetri, George D. ;
van Oosterom, Allan T. ;
Garrett, Christopher R. ;
Blackstein, Martin E. ;
Shah, Manisha H. ;
Verweij, Jaap ;
McArthur, Grant ;
Judson, Ian R. ;
Heinrich, Michael C. ;
Morgan, Jeffrey A. ;
Desai, Jayesh ;
D Fletcher, Christopher ;
George, Suzanne ;
Bello, Carlo L. ;
Huang, Xin ;
Baum, Charles M. ;
Casali, Paolo G. .
LANCET, 2006, 368 (9544) :1329-1338
[8]   KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients [J].
Gajiwala, Ketan S. ;
Wu, Joe C. ;
Christensen, James ;
Deshmukh, Gayatri D. ;
Diehl, Wade ;
DiNitto, Jonathan P. ;
English, Jessie M. ;
Greig, Michael J. ;
He, You-Ai ;
Jacques, Suzanne L. ;
Lunney, Elizabeth A. ;
McTigue, Michele ;
Molina, David ;
Quenzer, Terri ;
Wells, Peter A. ;
Yu, Xiu ;
Zhang, Yan ;
Zou, Aihua ;
Emmett, Mark R. ;
Marshall, Alan G. ;
Zhang, Hui-Min ;
Demetri, George D. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (05) :1542-1547
[9]   Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST [J].
Gronchi, Alessandro ;
Fiore, Marco ;
Miselli, Francesca ;
Lagonigro, Maria Stefania ;
Coco, Paola ;
Messina, Antonella ;
Pilotti, Silvana ;
Casali, Paolo Giovanni .
ANNALS OF SURGERY, 2007, 245 (03) :341-346
[10]   PDGFRA activating mutations in gastrointestinal stromal tumors [J].
Heinrich, MC ;
Corless, CL ;
Duensing, A ;
McGreevey, L ;
Chen, CJ ;
Joseph, N ;
Singer, S ;
Griffith, DJ ;
Haley, A ;
Town, A ;
Demetri, GD ;
Fletcher, CDM ;
Fletcher, JA .
SCIENCE, 2003, 299 (5607) :708-710